Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on SHAFTESBURY PLC. We currently have 18 research reports from 2 professional analysts.
|04Apr17 10:52||RNS||Block listing Interim Review|
|04Apr17 10:49||RNS||Block listing Interim Review|
|29Mar17 15:11||RNS||Director/PDMR Shareholding|
|09Mar17 12:41||RNS||Holding(s) in Company|
|07Mar17 16:02||RNS||Director/PDMR Shareholding|
|02Mar17 14:32||RNS||Holding(s) in Company|
|27Feb17 16:46||RNS||Notice of Results|
Frequency of research reports
Research reports on
Panmure Morning Note 05-02-16
05 Feb 16
The trading update this morning confirms that Shaftesbury's central London villages remain a major tourist attraction for London. The group curates the portfolio well so that streets become destinations with a unique character. The portfolio could not be replicated and positioned with excellent access to transport and the new Crossrail stations, footfall will continue to be amongst the highest in the UK. This will continue to drive demand and push up rents, which remain attractive compared to Regent Street, Oxford Street and Covent Garden. We think that the current weakness provides investors with an excellent opportunity to add to positions. We retain our BUY recommendation and 1106p target price (10% premium to one year forward NAV).
Panmure Morning Note 24-11-15
24 Nov 15
Shaftesbury continually delivers a strong and consistent performance. The group benefits from its Central London focus so that its c600 shops, restaurants and bars enjoy footfall of 40m-50m pa creating a vibrancy which is hard to beat globally and strong demand for its premises. The model is well articulated, established and diligently executed. These results should please the market as they beat consensus for NAV/s, which rose 21.9% to 869p. The outlook remains positive, underpinned by domestic growth in retail sales and high tourist footfall. Shaftesbury is our conviction Buy with a target valuation of 1106p.
Panmure Research - Conviction List Q4 2015 01-10-15
01 Oct 15
9.2% outperformance in Q3 sounds good, but set against a market that fell 9.1% this is hardly a great result. The disparity of performance was enormous with a couple of true mistakes in the Mining and Oil & Gas sector taking a heavy toll. For Q4 we have cut some losses and introduced Greene King, Microfocus and Wentworth on the Long calls with two new high conviction Short calls in Rolls Royce and Majestic Wine. Total outperformance since 2010 is 114% with 2 negative quarters out of 28. It seems there may be some alpha in our analyst's stock knowledge.
Panmure Morning Note 30-09-15
30 Sep 15
Shaftesbury has released a short trading update today highlighting progress with two major schemes and the continued strong trading conditions for its tenants in the core west end of London. We look forward to the results due 11 November 2015 which we anticipate will be strong with an estimated 16.3% rise in NAV/s to 830p. We continue to believe that the shares are undervalued since the estate value does not reflect the unique portfolio which could not be replicated in the heart of London. We retain our BUY recommendation and 1106p target price.
N+1 Singer - Uncovered Gems - Speed Dating Lunch - A Famous Five for the future?
12 Apr 17
On Friday we hosted our third “speed dating” lunch with the management of five very interesting and contrasting companies not under our formal coverage: Be Heard, Byotrol, Gfinity, Oxehealth and Plant Impact. Each company gave a concise and punchy overview of its business and investment case to a group of fund managers, before rapid fire Q&A. Below we summarise our thoughts on each company with more details inside the note, plus some relevant slides. We believe that all five companies are well-managed and well worth a closer look - we intend to repeat this efficient and popular format for engaging with management teams.
N+1 Singer - Small-cap quantitative research - Growth style screen revamp and 10 focus stocks
06 Apr 17
We have reviewed the performance of our consistent growth screen since the previous refresh on 27 September 2016 and revamped the selection parameters to focus more on forecast sales and EPS growth going forward. In the period under review the consistent growth style screen outperformed the small-cap benchmark by c. 6% and underperformed the microcap index by a similar amount. Interestingly, although growth doesn’t always seem to be defensive as might be expected, however it appears right to buy growth on dips caused by or coincident with wider market volatility. In the new forecast growth screen we take a close look at 10 focus stocks. We will monitor performance and refresh it in three to four months time.
Non Life Insurance - Growing impact of hacks on share prices
18 Apr 17
Our November 2016 Cyber report flagged the growing impact of cyber attacks on quoted companies, noting that Yahoo’s breach would inevitably negatively impact Verizon’s offer price, which it did. A report by CGI and Oxford Economics has found that, to date,severe hacks on UK companies permanently reduced their share price by 1.8% - or approximately a £120m hit to MCap for a FTSE 100 firm. With GDPR coming into effect next year, we expect more headlines. That has got to be good for cyber insurers and cyber security firms.
UK Housebuilding Sector: Q1 2017
10 Apr 17
Baron King of Lothbury, also known as Mervyn King former Governor of the Bank of England, is married to Barbara, a Finnish lady. She was his girlfriend in 1970 but distance and steam-driven telecoms conspired to keep them apart. Barbara went on to marry someone else and divorce - before being reunited with King in the late 1990s. They married in 2007 and King, who had never had children, was presented with two step-children and four grandchildren; and, in a Sunday Times interview, he quoted the Finnish apothegm “Grandchildren are the dessert of life”.
03 Apr 17
After much heralding, MIFID II is finally beginning to have an impact on the business of investment research, though its true ramifications might take years to be seen. The role of analyst research is widely misunderstood. It is not all about the conclusion: the rating and price target. The real content of research is about what is discounted in the current share price and what assumptions would produce different outcomes.